Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics (NASDAQ: PSTV) presented new data for REYOBIQ™ (rhenium Re186 obisbemeda) from its Phase 1 ReSPECT-LM trial for Leptomeningeal Metastases (LM) at the 2025 Nuclear Medicine and Neurooncology Conference. Key findings include:
The trial demonstrated significant clinical benefits with a 76% Clinical Benefit Rate (13/17 patients showing partial response or stable disease) and 87% clinical response rate based on physician evaluation. The treatment showed dose-dependent effectiveness, reaching 253Gy in Cohort 5.
Notably, 5 out of 7 patients who showed >80% reduction in LM tumor cells survived at least one year after initial treatment, with three receiving additional treatment under compassionate use. RNA sequencing revealed early tumor cell death and enhanced immune response, while maintaining a favorable safety profile with limited dose-limiting toxicities.
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO Marc H. Hedrick, M.D., will be available for one-on-one meetings from 9:00 AM to 3:00 PM ET. Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
Plus Therapeutics (PSTV) has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will serve as chair of the Audit Committee and on the Compensation Committee. Guse brings 30 years of professional experience, including a decade as CFO, General Counsel and Secretary at Atossa Therapeutics, a NASDAQ-listed company focused on breast cancer treatments.
Currently serving as Chief Legal Officer at NYSE-listed DDC Enterprise , Guse's background includes roles as a partner in top international law firms and as a Certified Public Accountant with a Big 4 firm. He holds a J.D. from Santa Clara University Law School and an M.B.A. from California State University, Sacramento.
Plus Therapeutics is developing targeted radiotherapeutics for central nervous system cancers, with key products including REYOBIQ™ and CNSide.
Plus Therapeutics (PSTV) has released new data from its Phase 1 ReSPECT-LM dose escalation trial for REYOBIQ™ (rhenium Re186 obisbemeda) in treating Leptomeningeal Metastases. The data will be presented at the Nuclear Medicine and Neurooncology conference in Vienna.
Key findings include:
- Dose-dependent increase in absorbed dose to cranial and spinal subarachnoid space, reaching 253Gy in Cohort 5
- 31% of patients (5 out of 16) showed partial response in neuroimaging
- 75% Clinical Benefit Rate through day 112 based on neuroimaging
- 86% Clinical Benefit Rate based on physician evaluation
- No dose limiting toxicity in first four cohorts; grade 4 thrombocytopenia observed in Cohorts 5 and 6
RNA sequencing revealed early induction of apoptosis, followed by innate immune response and increased T cells with adaptive immune response by Day 28.
Plus Therapeutics (PSTV) has reported its Q4 and full year 2024 financial results, highlighting significant developments in its CNS cancer therapeutics programs. The company secured a $15 million private placement financing, regaining Nasdaq compliance and extending runway into 2026, along with a $2 million grant advance from CPRIT.
Key highlights include FDA brand name approval for REYOBIQ, promising Phase 1 clinical trial results showing doubled median survival rates for glioblastoma patients, and FDA Orphan Drug Designation for leptomeningeal metastases treatment. The company strengthened its management team and expanded its agreement with Telix IsoTherapeutics for Rhenium-186 supply.
Financial results show $3.6 million in cash and investments as of December 31, 2024, $5.8 million in grant revenue, and a net loss of $13.0 million ($1.95 per basic share) for 2024.
Plus Therapeutics (Nasdaq: PSTV) announces FDA's conditional acceptance of REYOBIQ™ as the proprietary name for its lead therapeutic candidate. REYOBIQ™ (rhenium Re186 obisbemeda) is currently under clinical investigation for treating Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM), both central nervous system (CNS) cancers.
The company must submit a request for proprietary name review when filing the marketing application (NDA). This branding initiative aims to help investigators, investors, and potential patients better connect with the rhenium-based radiotherapeutic beyond its chemical composition.
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 27, 2025 after market close.
The company's management team will host a conference call and webcast at 5:00 p.m. ET to discuss financial results and provide a corporate update. Participants can pre-register through a dial-in link and are advised to join 15 minutes before the start time. A replay will be available on the company's website, with the webcast remaining accessible for 90 days following the live call.
Plus Therapeutics (Nasdaq:PSTV) has announced a private placement with expected gross proceeds of $15.0 million. The offering consists of 28,042,140 common units priced at $0.66 per unit, with each unit including one share of common stock (or pre-funded warrant) and two series of warrants.
Of the total units, 22,727,270 are for new capital subscriptions, while 5,314,870 units are exchanged for canceling existing senior convertible promissory notes. The Series A Warrants have an exercise price of $1.32 and a 60-month term, while the Series B Warrants are priced at $1.98 with a 30-month term.
The transaction is expected to close around March 4, 2025, subject to conditions including Nasdaq delisting confirmation by March 31, 2025. The proceeds will be used for repaying outstanding promissory notes, warrant repurchases, and general corporate purposes.
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement as of March 7, 2025. The company's common stock will maintain its listing and continue trading on The Nasdaq Capital Market.
Plus Therapeutics (PSTV) has published promising Phase 1 clinical trial results for Rhenium (186Re) Obisbemeda in treating glioblastoma (GBM) in Nature Communications. The study demonstrated significant survival benefits:
Key findings from the trial of 21 patients include:
- Median overall survival of 11 months, exceeding the standard care's 8-month survival rate
- Patients receiving >100 Gy achieved 17-month median survival, compared to 6 months for those receiving <100 Gy
- Treatment doses up to 22.3 mCi showed no dose-limiting toxicity
- Achieved tumor radiation doses up to 739.5 Gy without significant toxicity
The company is currently enrolling patients in its ReSPECT-GBM Phase 2 trial at leading medical centers.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
